UAE

Under the new framework, Arcera Life Sciences will collaborate with M42 to harness genomics data and explore disease prevalence patterns across targeted genetic and rare conditions.

The hospital introduced the technology as part of its broader strategy to expand minimally invasive surgical options and align with global standards in clinical care.

The plan follows Arada’s acquisition of a controlling stake in Reem Hospital, marking the company’s entry into the healthcare sector as it expands its presence across non-residential industries.

Alzheimer’s disease is characterized by the accumulation of tau protein in the brain, which gradually damages nerve cells and impairs memory and cognitive function.

Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management.

The innovation aims to enhance fluid drainage, speed up recovery, and potentially reduce the need for additional corrective procedures.

Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.

Once fully operational, the hub is expected to enable access to treatment for more than 2.6 million patients across a population of more than 1 billion people.

The report estimates that improved interventions could help over 1.2 million adults transition out of obesity by 2031.

The initiative integrates Johnson & Johnson’s Polyphonic™ open digital ecosystem with DOH Abu Dhabi and leading technology partners, including Amazon Web Services (AWS) and NVIDIA.